FAQ: Cybin Inc. Executives Presenting at TD Cowen Neuropsychiatry & Epilepsy Summit
Summary
Cybin Inc. announced that its Chief Medical Officer and Chief Business Officer will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. This presentation highlights Cybin's ongoing development of next-generation neuropsychiatry treatments, including CYB003 and CYB004, which have received Breakthrough Therapy Designation and are in advanced clinical trials.
What is the main announcement in this content?
Cybin Inc. announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 9:20 a.m. ET.
Who are the Cybin executives presenting at the summit?
Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will represent Cybin Inc. at the TD Cowen summit, participating in a fireside chat discussion.
When and where is the TD Cowen Neuropsychiatry & Epilepsy Summit taking place?
The summit is scheduled for September 17, 2025, at 9:20 a.m. ET. The specific physical location is not provided in the content, but it is TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit.
What does Cybin Inc. do as a company?
Cybin is a clinical-stage neuropsychiatry company developing next-generation treatment options for mental health conditions. They are a late-stage breakthrough company committed to revolutionizing mental healthcare with novel drugs that provide effective and durable results for patients.
What are Cybin’s main drug development programs mentioned?
Cybin is developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder (with FDA Breakthrough Therapy Designation), and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.
Where can I find more information about Cybin Inc. and this announcement?
The full press release can be viewed at https://ibn.fm/KXmrj, and the latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.
What is the significance of Cybin executives presenting at this summit?
The presentation at TD Cowen’s prestigious neuropsychiatry summit provides Cybin with a platform to share their clinical developments and breakthrough therapies with the investment and medical communities, highlighting their progress in developing next-generation mental health treatments.
Where does Cybin operate geographically?
Cybin is operational in Canada, the United States, the United Kingdom, and Ireland, having been founded in 2019 as a global neuropsychiatry company.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 206063